Beantown Biotech

Beantown Biotech is a Boston-based Drug Discovery Contract Research Organization (CRO), specializing in Assay Development, Screening, and Lead Optimization for the Biotechnology, Health Care, and Pharmaceutical industries. Offering a diverse range of in vitro and cell-based screening platforms, the company prides itself on providing rigorous science, transparent communication, and prompt data reporting. Established in 2012, Beantown Biotech aims to deliver exceptional customer experiences and substantial value. With a focus on Biochemical, Cellular assays (AlphaLISA, HTRF, HiBiT, NanoBret, CTG/ Cyquant, ELISA, Luminescence, Fluorescence), MesoScale Discovery (MSD) Assays, High Content Imaging (Operetta), Live Cell Imaging (IncuCyte S3), Flow Cytometry, qPCR, Jess Western, and Biophysical Characterization (MST - Monolith, Tycho NT6), the company endeavors to meet the scientific needs of its clients as their dedicated "laboratory down-the-hall." With a focus on enhancing drug discovery and development processes, Beantown Biotech presents an intriguing investment opportunity for venture capital firms looking to capitalize on the evolving landscape of biotechnology and pharmaceutical research.